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We have developed a method for rapidly inactivating
proteins with rapamycin-induced heterodimeriza-
tion. Cells were stably transfected with siRNA-resis-
tant, FKBP-tagged subunits of the adaptor protein
(AP) complexes of clathrin-coated vesicles (CCVs),
together with an FKBP and rapamycin-binding
domain-containing construct with a mitochondrial
targeting signal. Knocking down the endogenous
subunit with siRNA, and then adding rapamycin,
caused the APs to be rerouted tomitochondria within
seconds. Rerouting AP-2 to mitochondria effectively
abolished clathrin-mediated endocytosis of trans-
ferrin. In cells with rerouted AP-1, endocytosed
cation-independent mannose 6-phosphate receptor
(CIMPR) accumulated in a peripheral compartment,
and isolated CCVs had reduced levels of CIMPR,
but normal levels of the lysosomal hydrolase
DNase II. Both observations support a role for AP-1
in retrograde trafficking. This type of approach,
which we call a ‘‘knocksideways,’’ should be widely
applicable as a means of inactivating proteins with
a time scale of seconds or minutes rather than days.
INTRODUCTION
Establishing the function of a protein can be difficult. Even
proteins that have been extensively characterized may remain
elusive when it comes to finding out precisely what they do.
A case in point is the adaptor protein (AP)-1 complex, which
packages cargo proteins into clathrin-coated vesicles (CCVs)
budding from intracellular membranes. In spite of numerous
studies on the phenotype of cells and organismswith AP-1 either
deleted or depleted, there is still some uncertainty about the
function of AP-1, in particular whether it facilitates trafficking
from the trans-Golgi network (TGN) to endosomes, from endo-
somes to the TGN, or both (Robinson, 2004). Theoretically, it
should be possible to determine the directionality of AP-1 traf-
ficking by looking for changes in the steady-state distribution
of cargo proteins that depend upon AP-1 for packaging.
However, AP-1 knockout and knockdown studies have pro-
duced conflicting results. In some experiments, cargo proteins
were found to accumulate in endosomal (Meyer et al., 2000) or
postendosomal (Foote and Nothwehr, 2006) compartments,324 Developmental Cell 18, 324–331, February 16, 2010 ª2010 Elsevwhile, in others, they accumulated in the Golgi region (Canuel
et al., 2008) or at the plasma membrane (Lubben et al., 2007).
The major problem with gene knockouts and knockdowns is
that one cannot assay the phenotype immediately, because
the cell still contains ‘‘old’’ protein that needs to be degraded
and/or diluted. In the case of long-lived proteins like AP-1
subunits, it can take several days for the protein concentration
to drop to <10% of control levels. During this time, the sorting
of cargo proteins is likely to become less and less efficient as
the levels of AP-1 diminish. Some of these cargo proteins may
be components of the trafficking machinery, such as SNAREs
(Peden et al., 2001). Thus, by the time the cells are analyzed,
other membrane proteins may be missorted, not as a direct
consequence of the AP-1 knockdown, but as a secondary effect,
due to the mislocalization of machinery. Another potential
problem is that knocking down one trafficking pathway may
lead to upregulation of other compensatory pathways (Damke
et al., 1995). Therefore, more rapid methods are needed in order
to investigate the immediate consequences of inactivating AP-1.
Ideally, such methods should be adaptable enough that they
could be applied to other proteins as well.
The usual strategy for inactivating a protein quickly is to add
a small molecule inhibitor that can readily cross the plasma
membrane. So far, only a tiny percentage of proteins can be
targeted by specific drugs, but, over the past 15–20 years,
a number of cell biologists have carried out small-molecule
screens to try to find new inhibitors of membrane traffic path-
ways (Takizawa et al., 1993; Macia et al., 2006). One such screen
identified a family of compounds that interfere with AP-1-depen-
dent trafficking between the TGN and endosomes in yeast
(Duncan et al., 2007). However, the precise mechanism of action
of these compounds is not clear, and, when used on mammalian
cells, the only clear phenotype was an increase in the perinuclear
localization of AP-1 by immunofluorescence.
An alternative strategy is to modify the protein of interest so
that it can be targeted by an existing drug. For instance, rapamy-
cin is a drug that can be used to form heterodimers between any
two proteins, as long as they are in the same compartment and
contain rapamycin-binding domains. Normally, rapamycin binds
first to FKBP12, a prolyl isomerase, and then the rapamycin-
FKBP12 complex binds to mammalian target of rapamycin
(mTOR), a kinase. When the FKBP domain from FKBP12 and
the FKBP and rapamycin-binding (FRB) domain from mTOR
are transplanted onto other proteins, these proteins will also
dimerize in the presence of rapamycin. Rapamycin-induced
heterodimerization has been used in a number of cell biological
studies to address questions such as whether ER and Golgi
membranes fuse during mitosis (Pecot and Malhotra, 2004),ier Inc.
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Figure 1. FKBP-Tagged AP Complexes
(A and B) Schematic diagrams of the strategy that was used.
(C–F) Stable cell lines expressing either a-FKBP (C and D) or g-FKBP
(E and F) were mixed with nontransfected cells and double labeled
for the construct and either total a or endogenous g (using a
species-specific antibody). The insets show higher magnification
views of the areas inside the boxes. Scale bar, 20 mm.
(G and H) Homogenates of control HeLa cells and cell lines expressing
either a-FKBP (G) or g-FKBP (H) were depleted of the endogenous
subunit, and western blots were probed with antibodies that recognize
both the endogenous protein and the tagged construct.
(I) Control and a-FKBP-expressing cells were depleted of endogenous
a using siRNA, and endocytosis of prebound 125I-labeled transferrin
(Tf) was measured. Data are presented as the means (±SE) from three
independent experiments.
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endocytosis (Zoncu et al., 2007) and intracellular trafficking
(Zoncu et al., 2009). Two recent studies in yeast used rapamycin
to inactivate nuclear proteins by sequestering them in the cyto-
plasm (Haruki et al., 2008; Geda et al., 2008). Rapamycin and
related compounds have also been used to attach signaling
molecules to the plasmamembrane, and thus constitutively acti-
vate them (Spencer et al., 1995; Belshaw et al., 1996; Graef et al.,
1997; Inoue et al., 2005). However, so far, there is no rapamycin-
based method that can be used to inactivate a wide range of
proteins with different subcellular distributions.
Another drug that binds to the FKBP domain is FK506, and an
artificial dimer of FK506, called FK1012, can be used to form
homodimers between FKBP-tagged proteins. Attaching an
FKBP domain to clathrin and then adding FK1012 to transfected
cells has been shown to cross-link the clathrin and disrupt the
normal cycle of clathrin assembly/disassembly, inhibiting cla-
thrin-mediated endocytosis by 70% (Moskowitz et al., 2003).
However, because this method can only be used to inactivate
proteins that naturally self-assemble into oligomers, it is not
very adaptable. Probably the most wide-ranging strategy for
perturbing proteins pharmacologically is one that makes use of
a modified FKBP or FRB domain, which renders tagged proteins
unstable. The proteins can be protected by the addition of a
synthetic ligand, and the ligand can then be withdrawn, causing
the proteins to be degraded. The advantage of this method is
that it can be applied to many different types of proteins, and it
has now been successfully used on whole animals as well asDevelopmental Con cultured cells (Stankunas et al., 2003; Banaszynski
et al., 2006, 2008). The disadvantage of this method is
that it is relatively slow: protein degradation after ligand
withdrawal has a t1/2 of at least 1 hr, during which time
extensive trafficking (and other activities) can occur.
We set out to develop a method that would be both
rapid and versatile. The idea was to relocate proteins
such as AP-1 to a subcellular compartment that does
not participate in either the secretory or the endocytic
pathway. To this end, we made use of a technique devel-
oped by workers in the cytoskeleton field, in which
proteins are recruited onto the mitochondrial outer
membrane (Bear et al., 2000). This is normally done by
attaching a mitochondrial targeting signal to a protein
that has a number of different binding partners. Thebinding partners accumulate on mitochondria, where they are
unavailable for their usual role. The cells seem to tolerate the
presence of ‘‘foreign’’ proteins on their mitochondria surprisingly
well, and this method has been used to provide information not
only about protein-protein interactions (Kessels and Qualmann,
2002), but also about protein function (Dwivedy et al., 2007).
However, because the mitochondrial construct first has to be
synthesized by the cells, the phenotype cannot be analyzed until
hours or days after transfection.
In the present study, we have combined mitochondrial rerout-
ing with rapamycin-induced heterodimerization in order to
acutely sequester proteins away from their normal site of action.
Two proteins were chosen for these experiments: the g subunit
of the AP-1 adaptor complex and, for comparison, the a subunit
of the AP-2 adaptor complex. Like AP-1, AP-2 is an adaptor for
CCVs, but it participates in endocytosis rather than intracellular
trafficking. Its role is much better understood than that of
AP-1, and there are more reagents and assays available. Here
we show that rapamycin-induced rerouting to mitochondria is
extremely rapid, and that it can provide new insights into both
protein dynamics and protein function.
RESULTS
FKBP-Tagged AP Complexes Behave Normally
The FKBP domain was inserted into the linker region of siRNA-
resistant, epitope-tagged versions of the a subunit of AP-2 and
the g subunit of AP-1 (Figures 1A and 1B), and the constructsell 18, 324–331, February 16, 2010 ª2010 Elsevier Inc. 325
Developmental Cell
Rapid Inactivation of Proteinswere stably transfected into HeLa cells. Immunofluorescence
showed that both constructs colocalized with the endogenous
and/or total protein (Figures 1C–1F), and siRNA knockdowns
showed that, in both cases, only the endogenous protein was
depleted by the siRNA (Figures 1G and 1H). To ensure that the
insertion of an FKBP domain does not inactivate the AP subunit,
we used a well-established assay for AP-2 function (Figure 1I).
Endocytosis of radioiodinated transferrin was measured in
three populations of cells: untreated cells, cells depleted of
endogenous a, and the a-FKBP-expressing cell line depleted
of endogenous a. The a-FKBP construct efficiently rescued the
knockdown phenotype, indicating that it is fully functional.
Rapamycin Reroutes Tagged APs to Mitochondria
Next, we designed a construct called Mito-YFP-FRB (Figures 1A
and 1B), consisting of the import signal of the yeast mitochon-
drial outer membrane protein Tom70p, which has been shown
to work in mammalian cells (Kessels and Qualmann, 2002),
followed by YFP as a reporter and the FRB domain. Figure 2A
demonstrates that Mito-YFP-FRB is correctly targeted to mito-
chondria, because it colocalizes with the mitochondrial marker
MTC02.We then generated clonal cell lines that coexpress either
a-FKBP or g-FKBP together with Mito-YFP-FRB. In the absence
of rapamycin, there was no colocalization between the two
constructs (Figures 2B and 2D). However, addition of rapamycin
for 10min caused the adaptors to be almost completely rerouted
to mitochondria (Figures 2C and 2E; see Figure S1 available
online).
To investigate the time course of the rapamycin response, we
transiently transfected our a-FKBP/Mito-YFP-FRB cell line with
mCherry-tagged s2 (another subunit of the AP-2 complex),
and then carried out live cell imaging. Figure 2F shows cells at
the time of addition of rapamycin, and Figure 2G shows the cells
9 s later. It is clear that the rapamycin response is already well
underway; indeed, we could see rerouting just 3 s after addition
of the drug, which was as quickly as we could capture the
images (Movie S1).
What happens to the rest of the CCV machinery in cells with
rerouted AP complexes? To compare the labeling patterns of
other CCV-associated proteins, we knocked down the endoge-
nous AP subunits in both singly and doubly transfected cell lines,
and then mixed the cells together and added rapamycin. Triple
labeling showed that some CCV-associated proteins, such as
Dab2 and epsinR, followed their respective APs onto mitochon-
dria. However, other proteins, including clathrin, did not (Fig-
ure 2H; Figure S2), indicating that the cells do not attempt to
form CCVs from mitochondrial membranes.
Transferrin Uptake Is Blocked in Cells with Rerouted
AP-2
To examine the effects of rerouting on AP function, we looked
first at AP-2. Transferrin uptake was quantified by flow cytometry
in two different cell lines that coexpress a-FKBP and Mito-YFP-
FRB, which had been depleted of endogenous a with siRNA.
Addition of rapamycin for 10 min produced a similar inhibition
of transferrin uptake to depleting AP-2 in control cells (Figure 3).
Thus, at least in the case of AP-2, rapamycin-induced rerouting
works just as well as a conventional knockdown. However,
the procedure takes 10 min instead of 4 days, which means326 Developmental Cell 18, 324–331, February 16, 2010 ª2010 Elsevthat we can investigate the early consequences of protein
inactivation.
CIMPR Is Mislocalized in Cells with Rerouted AP-1
Having established that the rapamycin system works well
on AP-2, we went on to investigate AP-1, looking first at the
localization of the cation-independent mannose 6-phosphate
receptor (CIMPR). The CIMPR is a receptor for lysosomal hydro-
lases, which binds the hydrolases in the TGN, delivers them to
endosomes, and then returns to the TGN for another round. At
steady state, the CIMPR normally localizes mainly to the TGN
and/or endosomes (the relative levels in each compartment
depend on cell type), but it occasionally travels out to the plasma
membrane, where it is rapidly retrieved by clathrin-mediated
endocytosis. In cells from AP-1 knockout mice, the CIMPR
was found to accumulate in a peripheral endosomal compart-
ment, supporting a role for AP-1 in retrograde traffic (Meyer
et al., 2000). However, because the cells had many days to
adjust to the lack of AP-1, one cannot rule out the possibility
that this phenotype was an indirect effect of the knockout.
Cells coexpressing g-FKBP and Mito-YFP-FRB were treated
with rapamycin for various lengths of time. For some experi-
ments, the cells were fed an antibody against the CIMPR during
the treatment. The cells were then fixed, and the localization of
either endocytosed anti-CIMPR or total CIMPRwas investigated
by immunofluorescence. Rapamycin caused both the internal-
ized antibody and the total receptor to accumulate in peripheral
rather than juxtanuclear membranes, but this was particularly
striking for the internalized antibody (Figures 4A and 4B;
Figure S3). We saw a similar but less dramatic phenotype
when we carried out a conventional AP-1 knockdown, while, in
control cells, rapamycin treatment for the same length of time
had no effect on CIMPR or antibody localization (Figure S3).
CIMPR Is Depleted in CCVs from Cells with Rerouted
AP-1, but DNase II Is Not
Although the experiments described above support a role for
AP-1 in retrograde traffic, the effects of the drug are not imme-
diately apparent (the cells in Figure 4 and Figure S3 were incu-
bated with rapamycin for 45 min). This is because it takes
some time to change the steady-state distribution of a
membrane protein by interfering with its packaging into CCVs.
Only a small fraction of the protein is present in CCVs at any
one time, so one has to wait for multiple rounds of CCV budding
and fusion before a change in the overall localization of the
protein is perceptible. Therefore, we used another method to
look for mislocalization: we isolated CCVs from the cells, either
with or without first treating themwith rapamycin. This gives us a
snapshot of the CCVs at the moment when the cells are homog-
enized, so it is ideally suited to the present study, because we
can analyze the phenotype of the cells within minutes of adding
the drug.
Cells coexpressing g-FKBP and Mito-YFP-FRB were first
treated with siRNA to knock down endogenous g. Half of the
dishes were then incubated with rapamycin for 10 min before
homogenization. CCVs were isolated and western blotting was
used to look for differences in the relative abundance of various
CCV components. A representative preparation is shown in
Figure 4C.ier Inc.
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Figure 2. Localization of Constructs and Effect of Rapamycin
(A) Cells expressing Mito-YFP-FRB were labeled with an antibody against a mitochondrial marker, MTC02.
(B–E) Stable cell lines coexpressing either a-FKBP (B and C) or g-FKBP (D and E) together with Mito-YFP-FRB were treated with 200 nM rapamycin for either
0 (B and D) or 10 (C and E) min. Electron micrographs of the same conditions are shown in Figure S1.
(F and G) Live-cell imaging of cells coexpressing a-FKBP and Mito-YFP-FRB, and transiently transfected with mCherry-tagged s2. See Movie S1 for the video
link. Rapamycin was added to the cells at time 0 (F), which corresponds to 1min in the video; the frames in (G) show the same cells 9 s later. The panels on the right
of (F) and (G) are higher magnification views of the areas inside the boxes.
(H) Localization of clathrin in cells with rerouted AP-2. Mixed populations of cells, expressing either a-FKBP only, or coexpressing a-FKBP and Mito-YFP-FRB,
were depleted of endogenous a, treated with 200 nM rapamycin for 10 min, and triple labeled for clathrin. Other triple-labeled images are shown in Figure S2.
Scale bars, 20 mm.
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Figure 3. Assay for AP-2 Function
Two different cell lines that stably express both
a-FKBP and Mito-YFP-FRB were depleted of
endogenous a and allowed to endocytose fluores-
cently labeled transferrin for 10 min, with or
without first treating with rapamycin for 10 min.
As a comparison, control cells, either left un-
treated or depleted of endogenous a, were also
allowed to endocytose fluorescent transferrin for
10 min. After stripping off surface-bound trans-
ferrin, internalized transferrin was quantified by
flow cytometry.
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Figure 4. Assays for AP-1 Function
(A and B) Cells coexpressing g-FKBP and Mito-YFP-FRB were depleted of
endogenous g with siRNA, and incubated with anti-CIMPR for 45 min at
37C, either without (A) or with (B) rapamycin. See also Figure S3. Scale bar,
20 mm.
(C) Cells coexpressing g-FKBP and Mito-YFP-FRB were depleted of endoge-
nous g with siRNA. Half of the cells were treated with rapamycin for 10 min
before homogenization, then CCVs were isolated and western blots probed
with the indicated antibodies.
(D) Blots of whole-cell homogenates and CCV preparations from a conven-
tional AP-1 g knockdown, probed with the same antibodies as in (C).
Developmental Cell
Rapid Inactivation of ProteinsIn the rapamycin-treated cells, the AP-1 complex was lost
from CCVs, and there was also a subtle but reproducible loss
of clathrin, while AP-2 levels remained constant. The CIMPR
was also depleted in CCVs prepared from cells with rerouted
AP-1. In contrast, DNase II, a hydrolase that we have previously
shown to be a bona fide CCV cargo protein (Borner et al., 2006),
and which is known to contain mannose 6-phosphate (Sleat
et al., 2005), was unaffected by rapamycin, indicating that its
packaging is not dependent on AP-1. Although it will be impor-
tant to follow up this observation by quantifying the levels of
other hydrolases in the CCV preparation by comparative proteo-
mics, the DNase II result is likely to be representative. The loss of
the CIMPR from the preparation, with no concomitant loss of
DNase II, supports a role for AP-1 in the retrograde trafficking
of the empty receptor, rather than in the anterograde trafficking
of the receptor-hydrolase complex.
How does rapamycin-induced rerouting of AP-1 compare with
a conventional knockdown? Figure 4D shows CCVs isolated
from cells treated with siRNA for 4 days to deplete AP-1 g,
together with a matched control from the same experiment.
Although there is less CIMPR in the CCVs after the knockdown,
there is also less CIMPR in the homogenate, presumably
because it is degraded more rapidly, and this makes the differ-
ence in the CCVs less clear cut than in the rapamycin experi-
ment. DNase II is also somewhat reduced in the CCVs, but we
suspect that this is an indirect consequence of mislocalization
of the CIMPR. In contrast, AP-2 is actually increased in the
CCVs, possibly reflecting an attempt by the cells to compensate
for the loss of AP-1. Together, these results show that data
obtained from a conventional knockdown can sometimes be
difficult to interpret, and that acute depletion can provide
insights into protein function that are not apparent when proteins
are depleted gradually.
DISCUSSION
We have developed a strategy for investigating protein function,
in which we use rapamycin to trap the proteins on mitochondria.
Like all scientific methods, our strategy builds on techniques
developed by other researchers: rapamycin-mediated heterodi-
merization and mitochondrial mislocalization. However, to the
best of our knowledge, this is the first time that the two tech-
niques have been combined, and the synthesis of these two328 Developmental Cell 18, 324–331, February 16, 2010 ª2010 Elsevapproaches allows us to take advantage of the rapidity and
inducibility of the rapamycin system, together with the avail-
ability of mitochondria as a platform for sequestering proteins
away from their normal site of action. Because rapamycin-
induced rerouting is similar in some respects to a knockout or
a knockdown, but is much more rapid and puts the proteins inier Inc.
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name for it that (in British English) means ‘‘take by surprise’’:
a knocksideways.
In the case of AP-2, the knocksideways phenotype is very
similar to that of a conventional knockdown. However, in the
case of AP-1, mislocalization of endocytosed anti-CIMPR and
changes in the protein composition of CCVs are more
pronounced in knocksideways cells than in a conventional
knockdown. This is most likely because AP-1 is depleted rapidly
in the knocksideways cells, but only very gradually in the knock-
down, giving the cells a chance to adjust. One potential caveat is
that the AP-1 binding partner, epsinR, and possibly other
proteins as well, follow AP-1 onto mitochondria in the rapamy-
cin-treated knocksideways cells (Figure S2), so we cannot
formally rule out the possibility that the loss of one or more other
proteins also contributes to the knocksideways phenotype.
Nevertheless, both the antibody uptake assay and the CCV
isolation assay support a role for AP-1 in the TGN-to-endosome
pathway, adding to the weight of evidence implicating AP-1 in
retrograde rather than anterograde trafficking (Bonifacino and
Rojas, 2006).
How does the knocksideways approach compare with other
methods for perturbing protein function? The time scale is
approximately three to four orders of magnitude faster than an
siRNA knockdown, and approximately one to two orders of
magnitude faster than the only other drug-based method that
can be applied to a wide range of proteins: chemically controlled
degradation with a destabilizing FKBP domain (Banaszynski
et al., 2006). The kinetics of rerouting reflect the speed with
which adaptors cycle on and off membranes: fluorescence
recovery after photobleaching experiments show that, at
37C, bleached-coat proteins are replaced with a half-time of
10–20 s (Wu et al., 2003; Puertollano et al., 2003), and this
occurs even in the absence of vesicle budding. Thus, rapamy-
cin-induced rerouting occurs over a similar time frame as the
transient protein-protein and protein-lipid interactions that take
place inside the cell, which makes it ideal for studying this type
of event in vivo.
Why are the adaptors recruited so readily onto mitochondria,
instead of rebinding to the membrane they came from? Part of
the reason must be that the interaction with mitochondria has
amuch higher affinity. The interaction between the FKBP domain
and rapamycin, and between the FKBP-rapamycin complex and
the FRB domain, both have a Kd of <1 nM (Bayle et al., 2006). In
contrast, normal recruitment of adaptors onto membranes
occurs through several low-to-moderate affinity interactions,
typically in the lowmicromolar range (Owen et al., 2004). In addi-
tion, the FKBP-rapamycin-FRB interaction has a very slow off
rate: dissociation of rapamycin from the FKBP domain has
been reported to have a t1/2 of17.5 hr (Hosoi et al., 1999). Mito-
chondria are present throughout the cell, so they would always
be in close proximity to coat proteins when they dissociate
from membranes, and, once an adaptor had bound to a mito-
chondrion, the interaction would be essentially irreversible and
the adaptor would no longer be part of the cycling pool.
Although setting up the knocksideways system for a particular
protein is fairly labor intensive, requiring doubly transfected cell
lines and a robust knockdown-rescue system, the approach is
one that could lend itself to many different types of proteins, asDevelopmlong as they are either cytosolic or transiently associated with
membranes. Proteins in this category include other types of
coats, such as COPI and COPII, which are difficult to study by
siRNA knockdown, because they are essential for cell viability,
as well as other proteins involved in membrane traffic, such as
ARF and Rab GTPases, cytoskeletal motors, and tethering
complexes. In addition, many proteins involved in cell signaling
cycle back and forth between cytosol and membranes, and
thus they too could be explored by the knocksideways method.
Although, so far, we have looked only at HeLa cells, mitochon-
drial rerouting could be used on other cell types, such as yeast
and Drosophila cells, as well as on more complex organisms.
We are currently in the process ofmaking transgenicmice, which
will constitutively express a mitochondrial targeting signal
attached to a modified FRB domain, called FRB*. FRB* has
a point mutation that enables it to bind to a rapamycin analog,
AP21967, which cannot bind the wild-type FRB domain (Bayle
et al., 2006), thus circumventing any problems that might arise
from inhibition of mTOR-mediated signaling. The plan is to
mate these mice with knockin mice that have the FKBP domain
inserted into their AP-1 g gene, to generate a knocksideways
mouse model. Although still in its early stages, this approach, if
successful, should enable researchers to rapidly inactivate
proteins of interest not only in cultured cells, but also in whole
animals, and thus explore the role of the proteins in cell type-
specific pathways.
EXPERIMENTAL PROCEDURES
Constructs, Cell Lines, and Knock Downs
The a-FKBP construct was based on a pIRESneo2 plasmid encoding an
siRNA-resistant form of a, which includes a brain-specific insert that acts as
an epitope tag (Motley et al., 2006). The FKBP coding sequence was amplified
by PCR and inserted into the linker region of a. The open reading frame was
sequenced, the plasmid was transfected into HeLaM cells, and clonal cell lines
were isolated as previously described (Motley et al., 2006).
For the g-FKBP construct, a QuikChange mutagenesis kit (Stratagene) was
used to introduce silent mutations into mouse g cDNA to make it siRNA-resis-
tant (see below) and to add a new restriction site, whichwas then used to insert
the brain-specific epitope and the FKBP domain. After sequencing the open
reading frame, the construct was moved into a retroviral vector, pLXIN, with
a modified polylinker (a kind gift from A. Peden, CIMR). Virions were isolated
from packaging cells and used to infect HeLaM cells, and stable cell lines
were selected with G418.
The Mito-YFP-FRB construct was based on a pEYFP-FRB plasmid (kindly
provided by O. Glebov, MRC Laboratory of Molecular Biology, Cambridge,
UK). The N-terminal sorting signal of Tom70pwas amplified by PCR from yeast
genomic DNA and cloned into the plasmid, then the Mito-YFP-FRB coding
sequence was moved into the retroviral vector pQCXIH (Clontech), which
carries a hygromycin resistance gene, and stable cell lines were selected as
above.
The siRNA targeting AP-2 a (a-2) has already been described (Motley et al.,
2006). The g-FKBP construct wasmade resistant to siRNA D-019183-02-0050
(Dharmacon) (g-SP), which has the sequence, GAAGAUAGAAUUCACCUUU.
Both siRNAs were used at a final concentration of 100 nM, with hits on Days 1
and 3, and assays carried out on Day 5, as previously described (Motley et al.,
2003).
Rapamycin (Sigma) was prepared as a 1 mg/ml stock in ethanol and used at
a concentration of 200 nM.
Immunofluorescence and Western Blotting
Cells were prepared for immunofluorescence either by fixing with 3.7% para-
formaldehyde and permeabilizing with 0.1%Triton X-100, or by fixing/permea-
bilizing with methanol at 20C, as previously described (Motley et al., 2003).ental Cell 18, 324–331, February 16, 2010 ª2010 Elsevier Inc. 329
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Improvision OpenLab software. Western blots were prepared as previously
described (Borner et al., 2006), with cell homogenates, high-speed superna-
tants from CCV preparations, or isolated CCVs as samples (see below).
Primary antibodies that had been made in house include rabbit antisera
against clathrin heavy chain, AP-2 aC, AP-1 g, epsinR, CIMPR, and the epitope
used for tagging the AP subunits, A706–727 (Ball et al., 1995). Other primary
antibodies include commercially available monoclonal antibodies against
AP-1 g (mAb100/3; Sigma), AP-2 a (BD), CIMPR (2G11; AbCam), and themito-
chondrial protein MTC02 (AbCam), polyclonal anti-GFP and anti-DNase II
(both fromAbCam), and polyclonal anti-CALM and anti-Dab2 (both fromSanta
Cruz Biotechnology). The monoclonal antibodies against AP-2 a (AP.6) and
clathrin heavy chain (X22) used for immunofluorescence were kind gifts from
F. Brodsky (UCSF). The antibody against GGA2 was a kind gift from D. Brooks
(Women’s and Children’s Hospital, North Adelaide, SA, Australia). Secondary
antibodies for immunofluorescence were purchased from Invitrogen. Labeling
on western blots was visualized with either 125I-protein A (Amersham) or HRP-
conjugated secondary antibodies (Sigma) followed by chemiluminescence.
Uptake Assays
Uptake of 125I-labeled transferrin was carried out as previously described
(Motley et al., 2003), prebinding the transferrin to the cells at 4C and then
warming them up for various lengths of time. Surface-bound, internalized,
and recycled counts were all quantified. The flow cytometry-based assay
has also been described (Motley et al., 2006); briefly, cells were trypsinized
and incubated with AlexaFluor 633-labeled transferrin at 4C to allow binding
to occur, then warmed to 37C for 10 min and chilled again. Unbound and
surface-bound label were both removed, and the cells were analyzed by
flow cytometry with a BD FACSCalibur. Uptake of anti-CIMPR was carried
out by diluting the antibody 1:5000 in tissue culture medium, inverting cover-
slips over drops of the antibody, and incubating at 37C. Because there is
relatively little CIMPR on the cell surface at steady state, incubations were
normally carried out for 45 min. The cells were then fixed and labeled with
secondary antibodies, as described above. To make sure that there was no
bias in scoring the phenotypes, the slides were coded and scrambled before
they were viewed.
Live Cell Imaging
Stably transfected cells expressing both a-FKBP and Mito-YFP-FRB were
transiently transfected with a plasmid encoding m-Cherry-tagged AP-2 s2,
constructed by moving the insert from ps2EGFP-C1 (a kind gift from T. Kirch-
hausen, Harvard Medical School) into pmCherry-C1 (Clontech). Imaging was
performed with a spinning disk confocal laser source mounted on a Zeiss
AxioObserver Z1 inverted microscope and driven by Improvision Volocity
Acquisition software. The images were collected every 3 s, and rapamycin
was added as a 103 stock (i.e., 2 mM) after 1 min.
Isolation of CCVs
Cells were grown until they formed confluent monolayers in 15 cm dishes. For
the rapamycin experiments, two of the dishes were treated with 200 nM
rapamycin for 10 min before homogenization, and two were left untreated.
Ten independent preparations were carried out, using two different cell lines
that coexpress g-FKBP and Mito-YFP-FRB, with consistent results. The
CCV protocol is based on differential centrifugation, and has been previously
described (Hirst et al., 2004; Borner et al., 2006).
Immuno-Electron Microscopy
For immunogold labeling, cells were fixed initially by adding an equal volume of
freshly prepared 4% paraformaldehyde/0.4% gluteraldehyde in 0.25 M
HEPES buffer (pH 7.4). After 2 min, the solution was removed and replaced
by 2% paraformaldehyde/0.2% glutaraldehyde in 0.25 M HEPES (pH 7.4).
Cells were incubated in this solution for 2 hr at room temperature and then
further processed as previously described (Hirst et al., 2009). g-FKBP and
a-FKBP were detected with A706–727 (Ball et al., 1995), and Mito-YFP-FRB
with anti-GFP. Double labeling was performed with protein A conjugated to
colloidal gold (Utrecht University) as previously described (Hirst et al., 2009).
Controls were carried out omitting the second antibody to ensure that
blockage was complete, and varying the order in which the antibodies were330 Developmental Cell 18, 324–331, February 16, 2010 ª2010 Elsevadded to ensure that the results were consistent. The grids were viewed
with a Phillips CM 100 transmission electron microscope (Philips Electron
Optics, Cambridge, UK) at an operating voltage of 80 kV.SUPPLEMENTAL INFORMATION
Supplemental Information includes three figures and one movie and can be
found with this article online at doi:10.1016/j.devcel.2009.12.015.
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